Breaking News Instant updates and real-time market news.

ANAB

AnaptysBio

$78.32

3.15 (4.19%)

06:50
08/07/18
08/07
06:50
08/07/18
06:50

AnaptysBio see cash and equivalents enough through the end of FY19

AnaptysBio expects that its cash, cash equivalents and investments will fund its current operating plan through the end of 2019.

  • 14

    Aug

ANAB AnaptysBio
$78.32

3.15 (4.19%)

07/19/18
FBCO
07/19/18
INITIATION
Target $104
FBCO
Outperform
AnaptysBio initiated with an Outperform at Credit Suisse
Credit Suisse initiated AnaptysBio with an Outperform and $104 price target.
07/09/18
JEFF
07/09/18
NO CHANGE
Target $145
JEFF
Buy
AnaptysBio can rally up to $30 on upcoming asthma data, says Jefferies
Jefferies analyst Biren Amin previews this quarter's readout of AnaptysBio's Phase IIa study testing ANB020 in severe asthma. The analyst's analysis suggests most biologics deliver 6%-9% improvement in lung function. A 7%-8% improvement likely drives $15-$20 of share upside while 9%-10% likely pushes the stock up $25-$30, Amin tells investors in a research note. He believes a the lower range of a 5%-6% improvement could trigger a selloff of $10-$15 per share and a true miss of less than 5% improvement could see the stock down $20-$25. He keeps a Buy rating on AnaptysBio with a $145 price target.
05/29/18
JMPS
05/29/18
NO CHANGE
JMPS
JMP says AnaptysBio weakness ahead of asthma read-out a buying opportunity
After Aimmune Therapeutics (AIMT) presented new results from its Phase 3 trial of AR101 in peanut allergy at a medical congress, JMP Securities analyst Konstantinos Aprilakis noted that shares of competitor AnaptysBio (ANAB) are off about 42% over the last three months. He remains a buyer of AnaptysBio on any weakness going into the top-line proof of concept data from the Phase 2a trial of ANB020 in eosinophilic asthma, which is expected in Q3. The analyst, who reminds investors that he assigns about $61/share for the eosinophilic asthma indication in his valuation of AnaptysBio, maintains an Outperform rating and $180 price target on AnaptysBio shares, which closed Friday at $77.90.
04/04/18
RBCM
04/04/18
DOWNGRADE
Target $86
RBCM
Sector Perform
AnaptysBio downgraded to Sector Perform at RBC Capital on ANB020 uncertainty
As reported earlier, RBC Capital analyst Kennen MacKay downgraded AnaptysBio to Sector Perform from Outperform and lowered his price target to $86 from $144. MacKay cites "increasing skepticism regarding ANB020's path forward in peanut allergy" as post-data credibility concerns create an unfavorable risk-reward going into the company's phase 2a asthma readout expected in Q3. While the analyst expects the ANB020 readout to show a benefit vs. placebo, the results may be "challenging to interpret" relative to the treatment's competition.

TODAY'S FREE FLY STORIES

AIR

AAR Corp.

$33.83

0.125 (0.37%)

11:23
06/20/19
06/20
11:23
06/20/19
11:23
Hot Stocks
AAR, Tawazun Economic Council and GAL sign joint repair management deal »

AAR announced a new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

GO

Grocery Outlet

$0.00

(0.00%)

11:22
06/20/19
06/20
11:22
06/20/19
11:22
Syndicate
Breaking Syndicate news story on Grocery Outlet »

Grocery Outlet indicated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

WORK

Slack Technologies

$0.00

(0.00%)

11:20
06/20/19
06/20
11:20
06/20/19
11:20
Syndicate
Breaking Syndicate news story on Slack Technologies »

Slack Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GNLN

Greenlane

$12.23

1.25 (11.38%)

11:19
06/20/19
06/20
11:19
06/20/19
11:19
Recommendations
Greenlane analyst commentary  »

Greenlane fundamentals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CCL

Carnival

$47.60

-5.25 (-9.93%)

11:18
06/20/19
06/20
11:18
06/20/19
11:18
Downgrade
Carnival rating change  »

Carnival downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

CTST

CannTrust

$5.31

-0.05 (-0.93%)

, CURR

CURE Pharmaceutical

$0.00

(0.00%)

11:17
06/20/19
06/20
11:17
06/20/19
11:17
On The Fly
Rising High: CannTrust launches U.S. operations with California JV »

In this week's "Rising…

CTST

CannTrust

$5.31

-0.05 (-0.93%)

CURR

CURE Pharmaceutical

$0.00

(0.00%)

CGC

Canopy Growth

$43.05

0.275 (0.64%)

ACRGF

Acreage Holdings

$0.00

(0.00%)

TLRY

Tilray

$47.00

1.55 (3.41%)

IIPR

Innovative Industrial Properties

$135.35

10.335 (8.27%)

ORTFD

Biome Grow

$0.00

(0.00%)

APHA

Aphria

$6.75

0.01 (0.15%)

ACB

Aurora Cannabis

$7.46

-0.025 (-0.33%)

MMNFF

MedMen

$0.00

(0.00%)

ORHOF

Origin House

$0.00

(0.00%)

KSHB

KushCo Holdings

$0.00

(0.00%)

CRON

Cronos Group

$16.50

0.655 (4.14%)

MLCPF

MediPharm Labs

$0.00

(0.00%)

CVSI

CV Sciences

$0.00

(0.00%)

CANN

General Cannabis

$0.00

(0.00%)

IGC

India Globalization Capital

$1.32

0.09 (7.32%)

KNHBF

ICC International Cannabis

$0.00

(0.00%)

NDVAF

INDIVA

$0.00

(0.00%)

OGRMF

Organigram

$0.00

(0.00%)

ELLXF

Elixinol Global

$0.00

(0.00%)

PLNHF

Planet 13 Holdings

$0.00

(0.00%)

MRRCF

Wayland Group

$0.00

(0.00%)

KHRNF

Khiron Life Sciences

$0.00

(0.00%)

LHSIF

Liberty Health Sciences

$0.00

(0.00%)

SNNVF

Sunniva

$0.00

(0.00%)

HMDEF

DionyMed Brands

$0.00

(0.00%)

SRUTF

Sproutly

$0.00

(0.00%)

GRWG

Grow Generation

$0.00

(0.00%)

HRVSF

Harvest Health & Recreation

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 21

    Jun

  • 25

    Jun

  • 26

    Jun

  • 27

    Jun

  • 28

    Jun

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

11:17
06/20/19
06/20
11:17
06/20/19
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

11:16
06/20/19
06/20
11:16
06/20/19
11:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KKR

KKR

$24.52

0.23 (0.95%)

11:15
06/20/19
06/20
11:15
06/20/19
11:15
Options
KKR put volume heavy and directionally bearish »

Bearish flow noted in KKR…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:15
06/20/19
06/20
11:15
06/20/19
11:15
General news
Treasury announced a $113 B in coupon sales for next week »

Treasury announced a $113…

11:15
06/20/19
06/20
11:15
06/20/19
11:15
General news
Breaking General news story  »

4-Week Bill Auction to be…

11:15
06/20/19
06/20
11:15
06/20/19
11:15
General news
Breaking General news story  »

8-Week Bill Auction to be…

BGNE

BeiGene

$124.98

4.98 (4.15%)

11:09
06/20/19
06/20
11:09
06/20/19
11:09
Hot Stocks
BeiGene announces Phase 1b results of zanubrutinib with Gazyva »

BeiGene announced results…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

PSNL

Personalis

$0.00

(0.00%)

11:09
06/20/19
06/20
11:09
06/20/19
11:09
Syndicate
Breaking Syndicate news story on Personalis »

Personalis indicated to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

AMRN

Amarin

$19.82

0.4 (2.06%)

11:08
06/20/19
06/20
11:08
06/20/19
11:08
On The Fly
Jefferies sees Amarin stock poised for even more gains »

Seeing the stock's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

STLD

Steel Dynamics

$29.25

-0.45 (-1.52%)

11:05
06/20/19
06/20
11:05
06/20/19
11:05
Options
Steel Dynamics call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSON

Misonix

$23.52

(0.00%)

11:04
06/20/19
06/20
11:04
06/20/19
11:04
Hot Stocks
Breaking Hot Stocks news story on Misonix »

Misonix up 39c to $24.17…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MLNT

Melinta Therapeutics

$5.28

-1.02 (-16.19%)

11:04
06/20/19
06/20
11:04
06/20/19
11:04
Recommendations
Melinta Therapeutics analyst commentary  »

Gabelli fears Melinta…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSON

Misonix

$23.52

(0.00%)

11:03
06/20/19
06/20
11:03
06/20/19
11:03
Hot Stocks
SEC tells Misonix investigation concluded, no enforcement action recommended »

Misonix announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PSNL

Personalis

$0.00

(0.00%)

10:59
06/20/19
06/20
10:59
06/20/19
10:59
Syndicate
Personalis indicated to open at $28, IPO priced at $17 »

Personalis (PSNL) priced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

AGCO

Agco

$75.20

0.33 (0.44%)

10:57
06/20/19
06/20
10:57
06/20/19
10:57
Conference/Events
Agco management to meet with Oppenheimer »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 24

    Jun

  • 25

    Jun

  • 26

    Jun

WORK

Slack Technologies

$0.00

(0.00%)

10:54
06/20/19
06/20
10:54
06/20/19
10:54
Syndicate
Breaking Syndicate news story on Slack Technologies »

Slack Technologies direct…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GDX

VanEck Vectors Gold Miners ETF

$24.79

0.82 (3.42%)

10:50
06/20/19
06/20
10:50
06/20/19
10:50
Options
Recent call buyer in Gold Miners ETF hit the mother lode on Fed stance »

Recent call buyer in Gold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMC

AMC Entertainment

$11.13

-0.39 (-3.39%)

10:45
06/20/19
06/20
10:45
06/20/19
10:45
Options
AMC Entertainment call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

10:45
06/20/19
06/20
10:45
06/20/19
10:45
General news
Breaking General news story  »

3-Month Bill Announcement…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.